Our goal is to create highly specific, stable and potent ligand-conjugated nucleic acid-based medicines for the treatment of a broad range of diseases.
RNA interference (RNAi) is a conserved natural defence mechanism against exogenous nucleic acids, brought about by RNAi triggers, including short interfering RNAs or siRNAs.
The discovery of RNAi was awarded the 2006 Nobel Prize for Physiology or Medicine and sparked the development of innovations which harnesses this mechanism to silence disease causing RNA.
RNAi is widely accepted as a feasible treatment modality for certain diseases where the disease causing nucleic acid/protein is not druggable by small molecules or biologics.
Cargene creates siRNA–based drugs which are delivered to target organs by specially conjugated ligands.
Our drug development pipeline consists of therapeutic candidates for a diverse set of clinical indications